Pfizer (PFE) and Alliance Foundation Trials said Thursday that results from a phase 3 trial of the drug Ibrance showed that adding it to standard-of-care therapies extended median progression-free survival by over 15 months in patients with metastatic breast cancer.
The study involved patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer, according to a joint statement.
It showed a median progression-free survival of 44.3 months for 261 patients treated with Ibrance in combination with anti-HER2 therapy and endocrine therapy, compared with a median PFS of 29.1 months for 257 patients treated with anti-HER2 therapy and endocrine therapy alone, Pfizer and AFT said.
Pfizer is providing funding support for the trial, which is sponsored by AFT and cancer research groups in the US, Germany, Italy, Spain, Australia, and New Zealand.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.